The future of healthcare is being shaped by scientific advancement, regulatory expansion, and global collaboration
Ozempic progresses from 0.25 mg to a maintenance dose of up to 1 mg, whereas Wegovy reaches a higher maintenance dose of 2.4 mg to support weight loss goals [52, 53]
"This concept could reshape how GLP-1RAs are prescribed across different disease states." The field is evolving in four directions at once: oral formulations, multi-agonist combinations, muscle preservation strategies, and expansion into disease areas beyond metabolic medicine
Other GLP 1 also made it to the list, including Ozempic ($20B) Zepbound ($13.5B) and Wegovy ($12.5B)
According to the report, a combination of slowing Ozempic growth, commercial missteps, and concerns about generic semaglutide in emerging markets has rattled investor confidence